血清胃蛋白酶原联合肿瘤标志物CEA、CA199、CA125在胃癌诊断中的价值研究

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the value of serum pepsinogen (PG)Ⅰ, PGⅠ/Ⅱ combined with tumor markers carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and cancer antigen 125 (CA125) in the diagnosis of gastric cancer. Methods Eighty patients with gastric cancer diagnosed by pathological biopsy from People′s Hospital of Yangjiang City from January 2019 to December 2020 were selected as the gastric cancer group, 80 patients with benign gastric lesions diagnosed at the same time were selected as the benign lesion group, and 60 healthy experiencers were selected as the control group. The levels of PGⅠ, PGⅠ/Ⅱ, CEA, CEA, CA199, CA125 and the sensitivity, specificity and accuracy of single detection and combined detection were compared among the three groups. Results The PGⅠand PGⅠ/Ⅱ in the gastric cancer group were lower than those of the benign lesion group and the control group, and the differences were statistically significant (P＜0.05). The levels of CEA, CA199, and CA125 in the gastric cancer group were higher than those of the benign lesion group and the control group, and the differences were statistically significant (P＜0.05). In gastric cancer group, the sensitivity and accuracy of combined detection were higher than those of single detection, and the differences were statistically significant (P＜0.05). The specificity decreased but remained good.Conclusion The combine detection of PGⅠ, PGⅠ/Ⅱ, CEA, CA199, and CA125 has high sensitivity, accuracy and good specificity, which can improve the diagnostic efficiency of gastric cancer.

Key words： Gastric cancer Pepsinogen Carcinoembryonic antigen Carbohydrate antigen 199 Glycoprotein antigen 125 Sensitivity Specificity

Received: 31 May 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I35/184

[1]	谢晓岚，徐萍，赖跃兴，等.新型胃癌筛查评分系统在卫生系统健康体检人员早期胃癌筛查中的应用[J].中华消化内镜杂志，2021，38（1）：33-37.
[2]	曹毛毛，李贺，孙殿钦，等.2000-2019 年中国胃癌流行病学趋势分析[J].中华消化外科杂志，2021，20（1）：102-109.
[3]	孟凡冬，李鹏，张澍田.早期胃癌内镜诊断的变迁[J].中华消化内镜杂志，2021，38（1）：13-17.
[4]	邱海波，周志伟.NCCN 胃癌临床实践指南2017 年第五版更新要点解读[J].中华胃肠外科杂志，2018，21（2）：160-164.
[5]	刘慧，王鹏，陈艳钊，等.多肿瘤标志物联合检测在胃癌辅助诊断中的临床价值探讨[J].中国卫生检验杂志，2020，30（17）：2064-2068，2079.
[6]	许伟龙，南永刚，李林，等.胃蛋白酶原联合多种肿瘤标志物检测在胃癌早期诊断中的价值[J].现代肿瘤医学，2017，25（16）：2622-2625.
[7]	茅溢恒，陆维，刘燕.胃功能三项、肿瘤标志物联合13C 呼气试验在胃早癌筛查体检中的临床价值[J].现代消化及介入诊疗，2019，24（12）：1474-1477.
[8]	马逸婷，周新华，周向阳.胃癌患者血清 CEA、AFP、CA724、CA125 的检测联合病理学检查的临床诊断效果[J].实用癌症杂志，2021，36（2）：312-315.
[9]	吴峰，周正钱，刘增勇，等.PGⅠ、PGⅡ、G-17 检测在胃癌及萎缩性胃炎诊断中的应用价值[J].中国当代医药，2019，26（5）：86-88.
[10]	南寿山，靳荣，贾惠娟，等.血清 G-17、PGⅠ、PGⅡ、Hcy在胃黏膜癌变进展中的表达及临床意义[J].世界华人消化杂志，2019，27（22）：1383-1390.
[11]	王宁，付立业，隋承光，等.胃癌患者血清中IGF-1 与CEA、CA125、CA199、CA724 水平的相关性分析及在胃癌诊断中的意义[J].中国实验诊断学，2021，25（2）：194-197.
[12]	郭苗.CA125、CA199 与胃癌病程发展及预后的关系[J].检验医学与临床，2020，17（14）：1960-1962.
[13]	吴春芳，孙倩昀，顾申枫，等.血清 AFP、CA199、GGT、ALP联检肝癌早期诊断价值[J].现代科学仪器，2021，38（2）：88-93.
[14]	梁碧瑜，谭国据，陈俏容，等.2 型糖尿病患者胃肠道恶性肿瘤标志物CA199 的变化及临床意义[J].中国医药科学，2021，11（14）：188-190.
[15]	茅肖娜，汪莉莉.血清miR-21 和CA199 对胰腺癌临床诊断的应用价值探讨[J].重庆医学，2018，47（17）：2319-2322.
[16]	谢春霞，张磊，王淑惠，等.PGCEACA-199CK 及 CK-MB联合检测在胃癌筛查中的应用价值探讨[J].浙江临床医学，2019，（10）：1310-1311，1314.
[17]	孙运涛.胃蛋白酶原联合肿瘤标志物 CA199、CA125 和CEA 对胃癌的诊断价值分析[J].中国实用医药，2019，14（16）：22-23.
[18]	彭咏，谢永林，周芳.口服胃肠超声检查联合血清肿瘤标记物对中老年胃癌的诊断价值[J].中国医药科学，2020，10（13）：155-158.